Results from a Search for Dark Matter in the Complete LUX Exposure

We report constraints on spin-independent weakly interacting massive particle (WIMP)-nucleon scattering using a 3.35×10^{4}  kg day exposure of the Large Underground Xenon (LUX) experiment. A dual-phase xenon time projection chamber with 250 kg of active mass is operated at the Sanford Underground Research Facility under Lead, South Dakota (USA). With roughly fourfold improvement in sensitivity for high WIMP masses relative to our previous results, this search yields no evidence of WIMP nuclear recoils. At a WIMP mass of 50  GeV c^{-2}, WIMP-nucleon spin-independent cross sections above 2.2×10^{-46}  cm^{2} are excluded at the 90% confidence level. When combined with the previously reported LUX exposure, this exclusion strengthens to 1.1×10^{-46}  cm^{2} at 50  GeV c^{-2}.

Setting up a Neuroscience Stroke and Rehabilitation Centre in Brunei Darussalam by a transcontinental on-site and telemedical cooperation

Due to the world-wide aging population, there is a need for specialist neurological knowledge, treatment and care. Stroke treatment is effective in reducing mortality and disability, but it is still not available in many areas of the world. We describe the set-up process of a specialized Neuroscience, Stroke and Rehabilitation Centre in Brunei Darussalam (BNSRC) in cooperation with a German hospital. This study details the setup of a stroke-, neurological intensive care- and neurorehabilitation unit, laboratories and a telemedical network to perform all evidence-based stroke treatments. All neurological on-site services and the telemedical network were successfully established within a short time. After setup, 1386 inpatients and 1803 outpatients with stroke and stroke mimics were treated. All evidence-based stroke treatments including thrombolysis and hemicraniectomy could be performed. It is possible to establish evidence-based modern stroke treatment within a short time period by a transcontinental on-site and telemedical cooperation.

Galectin-3 binding protein in human preterm infant umbilical cord plasma

BACKGROUND

Galectin-3 binding protein (Gal3BP) is a glycoprotein isolated in colostrum that may be an immunologically active component with effects on the neonatal immune system. This compound has been found in the blood of term newborn infants, but has not been studied in preterm infants.

OBJECTIVE

Compare umbilical cord plasma Gal3BP concentration between preterm and term infants.

STUDY DESIGN

Observational study of mother-infant pairs consented at UCSD Medical Center comparing umbilical cord plasma Gal3BP concentration in preterm and term infants. Umbilical cord plasma was collected at birth and stored at -80°C before Gal3BP analysis by ELISA. This study was powered to evaluate differences in preterm and term infant Gal3BP concentration. The secondary aim was to determine the effect of maternal and infant clinical factors on Gal3BP concentration.

RESULTS

A total of 64 preterm and 30 term umbilical cord plasma samples were analyzed. By univariate analysis, Gal3BP concentration was elevated in the setting of prematurity, maternal diabetes, antenatal steroid exposure, and increasing maternal parity (p <  0.05); and decreased in chorioamnionitis (p = 0.03). Using a multiple linear regression model prematurity, chorioamnionitis and maternal diabetes remained significant.

CONCLUSIONS

Umbilical cord plasma Gal3BP concentration is elevated in prematurity. This may reflect inflammatory states in infant and mother, but further study is warranted.

Long-term results following an anatomically based surgical technique for resection of colon cancer: a comparison with results from complete mesocolic excision

AIM

Complete mesocolic excision (CME) has been advocated as likely to improve the long-term oncological outcome of colon cancer resection, although there is a paucity of long-term results in the literature. The aim of this study was to supplement our previously published results on colon cancer resection based on a standardized technique of precise dissection along anatomical planes with high vascular ligation and to compare our long-term results with those of recent European studies of CME.

METHOD

Data were drawn from a prospective hospital registry of consecutive resections for colon cancer between 1996 and 2007, including follow-up to the end of 2012. The principal outcomes from potentially curative resections were 5-year Kaplan-Meier rates of local recurrence, systemic recurrence, overall survival and cancer-specific survival. Secondary outcomes for all resections were postoperative complications, number of lymph nodes retrieved and R0 status.

RESULTS

For 779 potentially curative resections the local recurrence rate was 2.1% (95% CI 1.3-3.4), the systemic recurrence rate was 10.2% (95% CI 8.1-12.7), the 5-year overall survival rate was 76.2% (95% CI 73.0-79.0) and the cancer-specific survival rate was 89.8% (95% CI 87.3-91.9). For all 905 resections, rates of 14 surgical complications were low and not dissimilar to those in a comparable study. The median lymph node count was 15 (range 0-113). R0 status was confirmed in 883/905 patients (97.6%; 95% CI 96.4-98.5).

CONCLUSION

For colon cancer, meticulous dissection along anatomical planes together with high vascular ligation results in few complications, a high R0 rate, low recurrence and high survival.

18th European Symposium on Radiopharmacy and Radiopharmaceuticals

OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

V. Radchenko, J.W. Engle, C. Roy, J. Griswold, M.F. Nortier, E.R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M.E. Fassbender

OP04 Comparison of [68Ga]FSC(succ-RGD)3 and [68Ga]NODAGA-RGD for PET imaging of αvβ3 integrin expression

Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo

OP05 A new NPY-Y1R targeting peptide for breast cancer PET imaging

Ait-Mohand Samia, Dumulon-Perreault Véronique, Guérin Brigitte

OP06 The influence of multivalency on CCK 2 receptor targeting

D. Summer, A. Kroess, C. Rangger, H. Haas, P. Laverman, F. Gerben, E. von Guggenberg, C.Decristoforo

OP07 SPECT Imaging of αvβ3 Expression by [99mTc(N)PNP43]- Bifunctional Chimeric RGD Peptide not Cross-Reacting with αvβ5

Cristina Bolzati, Nicola Salvarese, Fiorenzo Refosco, Laura Meléndez-Alafort, Debora Carpanese, Antonio Rosato, Michele Saviano, Annarita Del Gatto, Daniela Comegna, Laura Zaccaro

OP09 New dienophiles for the inverse-electron-demand Diels-Alder reaction and for pretargeted PET imaging

Emilie Billaud, Muneer Ahamed, Frederik Cleeren, Elnaz Shahbazali, Tim Noël, Volker Hessel, Alfons Verbruggen and Guy Bormans

OP10 New complexing agent for Al18F-labelling of heat-sensitive biomolecules: Synthesis and preclinical evaluation of Al18F-RESCA1-HAS

Cleeren F, Lecina J, Koole M, Verbruggen A and Bormans G

OP11 A novel versatile precursor efficient for F-18 radiolabelling via click-chemistry

B. Lugatoa, S. Stucchia, E.A. Turollaa, L. Giulianoa, S.Toddea, P. Ferraboschib

OP12 A general applicable method to quantify unidentified UV impurities in radiopharmaceuticals

R.P. Klok, M.P.J. Mooijer, N.H. Hendrikse, A.D. Windhorst

OP13 Development of [¹⁸F]Fluoro-C-glycosides to radiolabel peptides

Collet C., Petry N., Chrétien F., Karcher G., Pellegrini-Moïse N., Lamandé-Langle S.

OP14 A Microfluidic Approach for the 68Ga-labeling of PSMAHBED-CC and NODAGA-RGD

Sarah Pfaff, Cecile Philippe, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak

OP16 Surprising reactivity of astatine in the nucleophilic substitution of aryliodonium salts: application to the radiolabeling of antibodies

François Guérard, Yong-Sok Lee, Sébastien Gouard, Kwamena Baidoo, Cyrille Alliot, Michel Chérel, Martin W. Brechbiel, Jean-François Gestin

OP17 ⁶⁴Cu-NOTA-pertuzumab F(ab')₂ fragments, a second-generation probe for PET imaging of the response of HER2-positive breast cancer to trastuzumab (Herceptin)

Lam K, Chan C, Reilly RM

OP18 Development of radiohalogenated analogues of a avb6-specific peptide for high LET particle emitter targeted radionuclide therapy of cancer

Salomé Paillas, John Marshall, Jean-Pierre Pouget, Jane Sosabowski

OP19 Ligand Specific Efficiency (LSE) as a guide in tracer optimization

Emmanuelle Briard, Yves P. Auberson, John Reilly, Mark Healy, David Sykes

OP23 The radiosynthesis of an 18F-labeled triglyceride, developed to visualize and quantify brown adipose tissue activity

Andreas Paulus, Wouter van Marken Lichtenbelt,Felix Mottaghy, Matthias Bauwens

OP24 Influence of the fluorescent dye on the tumor targeting properties of dual-labeled HBED-CC based PSMA inhibitors

Baranski, Ann-Christin, Schäfer, Martin, Bauder-Wüst, Ulrike, Haberkorn, Uwe, Eder, Matthias, Kopka, Klaus

OP25 [18F]MEL050 as a melanin PET tracer : fully automated radiosynthesis and evaluation for the detection of pigmented melanoma in mice pulmonary metastases

Chaussard M, Hosten B, Vignal N, Tsoupko-Sitnikov V, Hernio N, Hontonnou F, Merlet P, Poyet JL, Sarda-Mantel L, Rizzo-Padoin N

OP26 Design and Preclinical Evaluation of Novel Radiofluorinated PSMA Targeting Ligands Based on PSMA-617

J. Cardinale, M. Schäfer, M. Benešová, U. Bauder-Wüst, O. Seibert, F. Giesel, U. Haberkorn, M. Eder, K. Kopka

OP27 A novel radiolabeled peptide for PET imaging of prostate cancer: 64Cu-DOTHA2-PEG-RM26

Mansour Nematallah, Paquette Michel, Ait-Mohand Samia, Dumulon-Perreault Véronique, Lecomte Roger, Guérin Brigitte

OP29 Biodistribution of [¹⁸F]Amylovis®, a new radiotracer PET imaging of β-amyloid plaques

Fernandez-Maza L, Rivera-Marrero S, Prats Capote A, Parrado-Gallego A, Fernandez-Gomez I, Balcerzyk M, Sablon-Carrazana M, Perera-Pintado A, Merceron-Martinez D, Acosta-Medina E, Rodriguez-Tanty C

OP30 Synthesis and preclinical evaluation of [11C]-BA1 PET tracer for the imaging of CSF-1R

Bala Attili, Muneer Ahamed, Guy Bormans

OP31 In vivo imaging of the MCHR1 in the ventricular system via [18F]FE@SNAP

C. Philippe, M. Zeilinger, T. Scherer, C. Fürnsinn, M. Dumanic, W. Wadsak, M. Hacker, M. Mitterhauser

OP32 Synthesis of the first carbon-11 labelled P2Y12 receptor antagonist for imaging the anti-inflammatory phenotype of activated microglia

B. Janssen, D.J. Vugts, G.T. Molenaar, U. Funke, P.S. Kruijer, F. Dollé, G. Bormans, A.A. Lammertsma, A.D. Windhorst

OP33 Radiosynthesis of a selective HDAC6 inhibitor [11C]KB631 and in vitro and ex vivo evaluation

Koen Vermeulen, Muneer Ahamed, Michael Schnekenburger, Mathy Froeyen, Dag Erlend Olberg, Marc Diederich, Guy Bormansa

OP34 Improving metabolic stability of fluorine-18 labelled verapamil analogues

Raaphorst RM, Luurtsema G, Lammertsma AA, Elsinga PH, Windhorst AD

OP36 Development of a novel PET tracer for the activin receptor-like kinase 5

Lonneke Rotteveel, Uta Funke, Peter ten Dijke, Harm Jan Bogaard, Adriaan A. Lammertsma, Albert D. Windhorst

OP37 SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo

Lei Song, Sarah Able, Nadia Falzone, Veerle Kersemans, Katherine Vallis

OP38 Melanoma targeting with [99mTc(N)(PNP3)]-labeled NAPamide derivatives: preliminary pharmacological studies

Davide Carta, Nicola Salvarese, Wiebke Sihver, Feng Gao, Hans Jürgen Pietzsch, Barbara Biondi, Paolo Ruzza, Fiorenzo Refosco, Cristina Bolzati

OP39 [⁶⁸Ga]NODAGA-RGD: cGMP synthesis and data from a phase I clinical study

Roland Haubner, Armin Finkensted, Armin Stegmair, Christine Rangger, Clemens Decristoforo, Heinz Zoller, Irene J. Virgolin

OP44 Implementation of a GMP-grade radiopharmacy facility in Maastricht

Ivo Pooters, Maartje Lotz, Roel Wierts, Felix Mottaghy, Matthias Bauwens

OP45 Setting up a GMP production of a new radiopharmaceutical

Forsback, Sarita, Bergman Jörgen, Kivelä Riikka

OP48 In vitro and in vivo evaluation of 68-gallium labeled Fe3O4-DPD nanoparticles as potential PET/MRI imaging agents

M. Karageorgou, M. Radović, C. Tsoukalas, B. Antic, M. Gazouli, M. Paravatou-Petsotas, S. Xanthopouls, M. Calamiotou, D. Stamopoulos, S. Vranješ-Durić, P. Bouziotis

OP49 Fast PET imaging of inflammation using 68Ga-citrate with Fe-containing salts of hydroxy acids

A. S. Lunev, A. A. Larenkov, K.A. Petrosova, O. E. Klementyeva, G. E. Kodina

PP01 Installation and validation of 11C-methionine synthesis

Kvernenes, O.H., Adamsen, T.C.H.

PP02 Fully automated synthesis of 68Ga-labelled peptides using the IBA Synthera® and Synthera® Extension modules

René Martin, Sebastian Weidlich, Anna-Maria Zerges, Cristiana Gameiro, Neva Lazarova, Marco Müllera

PP03 GMP compliant production of ¹⁵O-labeled water using IBA 18 MeV proton cyclotron

Gert Luurtsema, Michèl de Vries, Michel Ghyoot, Gina van der Woude, Rolf Zijlma, Rudi Dierckx, Hendrikus H. Boersma, Philip H. Elsinga

PP04 In vitro Nuclear Imaging Potential of New Subphthalocyanine and Zinc Phthalocyanine

Fatma Yurt Lambrecht, Ozge Er, Mine Ince, Cıgır Biray Avci, Cumhur Gunduz, Fatma Aslihan Sarı

PP05 Synthesis, Photodynamic Therapy Efficacy and Nuclear Imaging Potential of Zinc Phthalocyanines

Kasim Ocakoglu, Ozge Er, Onur Alp Ersoz, Fatma Yurt Lambrecht, Mine Ince, Cagla Kayabasi, Cumhur Gunduz

PP06 Radio-U(H)PLC – the Search on the Optimal Flow Cell for the γ-Detector

Torsten Kniess, Sebastian Meister, Steffen Fischer, Jörg Steinbach

PP07 Radiolabeling, characterization & biodistribution study of cysteine and its derivatives with Tc99m

Rabia Ashfaq, Saeed Iqbal, Atiq-ur-Rehman, Irfan ullah Khan

PP08 Radiolabelling of poly (lactic-co.glycolic acid) (PLGA) nanoparticles with 99mTC

R Iglesias-Jerez, Cayero-Otero, L. Martín-Banderas, A. Perera-Pintado, I. Borrego-Dorado

PP09 Development of [¹⁸F]PD-410 as a non-peptidic PET radiotracer for gastrin releasing peptide receptors

Ines Farinha-Antunes, Chantal Kwizera, Enza Lacivita, Ermelinda Lucente, Mauro Niso, Paola De Giorgio, Roberto Perrone, Nicola A. Colabufo, Philip H. Elsinga, Marcello Leopoldo

PP10 An improved nucleophilic synthesis of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy) benzothiazole ([18F]FEDMBT), potential diagnostic agent for breast cancer imaging by PET

V.V. Vaulina, O.S. Fedorova, V.V. Orlovskaja, С.L. Chen, G.Y. Li, F.C. Meng, R.S. Liu, H.E. Wang, R.N. Krasikova

PP11 Internal radiation dose assessment of radiopharmaceuticals prepared with accelerator-produced 99mTc

Laura Meléndez-Alafort, Mohamed Abozeid, Guillermina Ferro-Flores, Anna Negri, Michele Bello, Nikolay Uzunov, Martha Paiusco, Juan Esposito, Antonio Rosato

PP12 A specialized five-compartmental model software for pharmacokinetic parameters calculation

Laura Meléndez-Alafort, Cristina Bolzati, Guillermina Ferro-Flores, Nicola Salvarese, Debora Carpanese, Mohamed Abozeid, Antonio Rosato, Nikolay Uzunov

PP13 Molecular imaging of the pharmacokinetic behavior of low molecular weight ¹⁸F-labeled PEtOx in comparison to ⁸⁹Zr-labeled PEtOx

Palmieri L, Verbrugghen T, Glassner M, Hoogenboom R, Staelens S, Wyffels L

PP14 Towards nucleophilic synthesis of the α-[18F]fluoropropyl-L-dihydroxyphenylalanine

V. V. Orlovskaja, O. F. Kuznetsova, O. S. Fedorova, V. I. Maleev, Yu. N. Belokon, A. Geolchanyan, A. S. Saghyan, L. Mu, R. Schibli, S. M. Ametamey, R. N. Krasikova

PP15 A convenient one-pot synthesis of [18F]clofarabine

Revunov, Evgeny, Malmquist, Jonas, Johnström, Peter, Van Valkenburgh, Juno, Steele, Dalton, Halldin, Christer, Schou, Magnus

PP16 BODIPY-estradiol conjugates as multi-modality tumor imaging agents

Samira Osati,Michel Paquette,Simon Beaudoin,Hasrat Ali,Brigitte Guerin, Jeffrey V. Leyton, Johan E. van Lier

PP17 Easy and high yielding synthesis of 68Ga-labelled HBED-PSMA and DOTA-PSMA by using a Modular-Lab Eazy automatic synthesizer

Di Iorio V, Iori M, Donati C, Lanzetta V, Capponi PC, Rubagotti S, Dreger T, Kunkel F, Asti M

PP18 Synthesis and evaluation of fusarinine C-based octadentate bifunctional chelators for zirconium-89 labelling

Chuangyan Zhai, Christine Rangger, Dominik Summer, Hubertus Haas, Clemens Decristoforo

PP19 Fully automated production of [18F]NaF using a re-configuring FDG synthesis module.

Suphansa Kijprayoon, Ananya Ruangma, Suthatip Ngokpol, Samart Tuamputsha

PP20 Extension of the Carbon-11 Small Labeling Agents Toolbox and Conjugate Addition

Ulrike Filp, Anna Pees, Carlotta Taddei, Aleksandra Pekošak, Antony D. Gee, Alex J. Poot, Albert D. Windhorst

PP21 In vitro studies on BBB penetration of pramipexole encapsulated theranostic liposomes for the therapy of Parkinson’s disease

Mine Silindir Gunay, A. Yekta Ozer, Suna Erdogan, Ipek Baysal, Denis Guilloteau, Sylvie Chalon

PP22 Factors affecting tumor uptake of 99mTc-HYNIC-VEGF165

Filippo Galli, Marco Artico, Samanta Taurone, Enrica Bianchi, Bruce D. Weintraub, Mariusz Skudlinski, Alberto Signore

PP23 Rhenium-188: a suitable radioisotope for targeted radiotherapy

Nicolas Lepareur, Nicolas Noiret, François Hindré, Franck Lacœuille, Eric Benoist, Etienne Garin

PP24 Preparation of a broad palette of 68Ga radiopharmaceuticals for clinical applications

Trejo-Ballado F, Zamora-Romo E, Manrique-Arias JC, Gama-Romero HM, Contreras-Castañon G, Tecuapetla-Chantes RG, Avila-Rodriguez MA

PP25 68Ga-peptide preparation with the use of two 68Ge/68Ga-generators

H. Kvaternik, D. Hausberger, C. Zink, B. Rumpf, R. M. Aigner

PP26 Assay of HEPES in 68Ga-peptides by HPLC

H. Kvaternik, D. Hausberger, B. Rumpf, R. M. Aigner

PP27 Preparation, in vitro and in vivo evaluation of a 99mTc(I)-Diethyl Ester (S,S)-Ethylenediamine- N,N´-DI-2-(3-Cyclohexyl) Propionic acid as a target-specific radiopharmaceutical

Drina Janković, Mladen Lakić, Aleksandar Savić, Slavica Ristić, Nadežda Nikolić, Aleksandar Vukadinović, Tibor J. Sabo, Sanja Vranješ-Đurić

PP28 90Y-labeled magnetite nanoparticles for possible application in cancer therapy

S. Vranješ-Đurić, M. Radović, D. Janković, N. Nikolić, G. F. Goya, P. Calatayud, V. Spasojević, B. Antić

PP29 Simplified automation of the GMP production of 68Ga-labelled peptides

David Goblet, Cristiana Gameiro, Neva Lazarova

PP30 Combining commercial production of multi-products in a GMP environment with Clinical & R&D activities

Cristiana Gameiro, Ian Oxley, Antero Abrunhosa, Vasko Kramer, Maria Vosjan, Arnold Spaans

PP31 ⁹⁹mTc(CO)3-labeling and Comparative In-Vivo Evaluation of Two Clicked cRGDfK Peptide Derivatives

Kusum Vats, Drishty Satpati, Haladhar D Sarma, Sharmila Banerjee

PP32 Application of AnaLig resin for 99mTc separation from molybdenum excess

Wojdowska W., Pawlak D.W., Parus L. J., Garnuszek P., Mikołajczak R.

PP33 Constraints for selection of suitable precursor for one-step automated synthesis of [18F]FECNT, the dopamine transporter ligand

Pijarowska-Kruszyna J, Jaron A, Kachniarz A, Malkowski B, Garnuszek P, Mikolajczak R

PP34 Gamma scintigraphy studies with 99mTc- amoxicillin sodium in bacterially infected and sterile inflamed rats

Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu

PP35 Preparation of 99mTc- Amoxicillin Sodium Lyophilized Kit

Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu

PP36 Outfits of Tracerlan FXC-PRO for 11C-Labeling

Arponen Eveliina, Helin Semi, Saarinen Timo, Vauhkala Simo, Kokkomäki Esa, Lehikoinen Pertti

PP37 Microfluidic synthesis of ω-[18F]fluoro-1-alkynes

Mariarosaria De Simone, Giancarlo Pascali, Ludovica Carzoli, Mauro Quaglierini, Mauro Telleschi, Piero A. Salvadori

PP38 Automated 18F-flumazenil production using chemically resistant disposable cassettes

Phoebe Lam, Martina Aistleitner, Reinhard Eichinger, Christoph Artner

PP39 The effect of the eluent solutions (TBAHCO3, Kryptand K2.2.2) on the radiochemical yields of 18F-Fluoromethylcholine

Surendra Nakka, Hemantha Kumara MC, Al-Qahtani Mohammed

PP40 [68Ga]Radiolabeling of short peptide that has a PET imaging potentials

Al-Qahtani, Mohammed, Al-Malki, Yousif

PP41 Is validation of radiochemical purity analysis in a public hospital in a developing country possible?

N Mambilima, SM Rubow

PP42 Improved automated radiosynthesis of [18F]FEPPA

N. Berroterán-Infante, M. Hacker, M. Mitterhauser, W. Wadsak

PP43 Synthesis and initial evaluation of Al18F-RESCA1-TATE for somatostatin receptor imaging with PET

Uta Funke, Frederik Cleeren, Joan Lecina, Rodrigo Gallardo, Alfons M. Verbruggen, Guy Bormans

PP44 Radiolabeling and SPECT/CT imaging of different polymer-decorated zein nanoparticles for oral administration

Rocío Ramos-Membrive, Ana Brotons, Gemma Quincoces, Laura Inchaurraga, Inés Luis de Redín, Verónica Morán, Berta García-García, Juan Manuel Irache, Iván Peñuelas

PP45 An analysis of the quality of 68Ga-DOTANOC radiolabelling over a 3 year period

Trabelsi, M., Cooper M.S.

PP46 In vivo biodistribution of adult human mesenchymal stem cells I (MSCS-ah) labeled with 99MTC-HMPAO administered via intravenous and intra-articular in animal model. Preliminary results

Alejandra Abella, Teodomiro Fuente, Antonio Jesús Montellano, Teresa Martínez, Ruben Rabadan, Luis Meseguer-Olmo

PP47 Synthesis of [¹⁸F]F-exendin-4 with high specific activity

Lehtiniemi P, Yim C, Mikkola K, Nuutila P, Solin O

PP48 Experimental radionuclide therapy with 177Lu-labelled cyclic minigastrin and human dosimetry estimations

von Guggenberg E, Rangger C, Mair C, Balogh L, Pöstényi Z, Pawlak D, Mikołajczak R

PP49 Synthesis of radiopharmaceuticals for cell radiolabelling using anion exchange column

Socan A, Kolenc Peitl P, Krošelj M, Rangger C, Decristoforo C

PP50 [68Ga]peptide production on commercial synthesiser mAIO

Collet C., Remy S., Didier R,Vergote T.,Karcher G., Véran N.

PP51 Dry kit formulation for efficient radiolabeling of 68Ga-PSMA

D. Pawlak, M. Maurin, P. Garnuszek, U. Karczmarczyk, R. Mikołajczak

PP52 Development of an experimental method using Cs-131 to evaluate radiobiological effects of internalized Auger-electron emitters

Pil Fredericia, Gregory Severin, Torsten Groesser, Ulli Köster, Mikael Jensen

PP53 Preclinical comparative evaluation of NOTA/NODAGA/DOTA CYCLO-RGD peptides labelled with Ga-68

R. Leonte, F. D. Puicea, A. Raicu, E. A. Min, R. Serban, G. Manda, D. Niculae

PP54 Synthesizer- and Kit-based preparation of prostate cancer imaging agent 68Ga-RM2

Marion Zerna, Hanno Schieferstein, Andre Müller, Mathias Berndt

PP55 Synthesis of pancreatic beta cell-specific [18F]fluoro-exendin-4 via strain-promoted aza-dibenzocyclooctyne/azide cycloaddition

Cheng-Bin Yim, Kirsi Mikkola, Pirjo Nuutila, Olof Solin

PP56 Automated systems for radiopharmacy

D. Seifert, J. Ráliš, O. Lebeda

PP57 Simple, suitable for everyday routine use quality control method to assess radionuclidic purity of cyclotron-produced 99mTc

Svetlana V. Selivanova, Helena Senta, Éric Lavallée, Lyne Caouette, Éric Turcotte, Roger Lecomte

PP58 Effective dose estimation using Monte Carlo simulation for patients undergoing radioiodine therapy

Marina Zdraveska Kochovska, Emilija Janjevik Ivanovska, Vesna Spasic Jokic

PP59 Chemical analysis of the rituximab radioimmunoconjugates in lyophilized formulations intended for oncological applications

Darinka Gjorgieva Ackova, Katarina Smilkov, Petre Makreski, Trajče Stafilov, Emilija Janevik-Ivanovska

PP61 The need and benefits of established radiopharmacy in developing African countries

Aschalew Alemu, Joel Munene Muchira, David Mwanza Wanjeh, Emilija Janevik-Ivanovska

PP62 University Master Program of Radiopharmacy – step forward for Good Radiopharmacy Education

Emilija Janevik-Ivanovska, Zoran Zdravev, Uday Bhonsle, Osso Júnior João Alberto, Adriano Duatti, Bistra Angelovska, Zdenka Stojanovska, Zorica Arsova Sarafinovska, Darko Bosnakovski, Darinka Gorgieva-Ackova, Katarina Smilkov, Elena Drakalska, Meera Venkatesh, Rubin Gulaboski

PP63 Synthesis and preclinical validations of a novel 18F-labelled RGD peptide prepared by ligation of a 2-cyanobenzothiazole with 1,2-aminothiol to image angiogenesis.

Didier J. Colin, James A. H. Inkster, Stéphane Germain, Yann Seimbille

Results on the Spin-Dependent Scattering of Weakly Interacting Massive Particles on Nucleons from the Run 3 Data of the LUX Experiment

We present experimental constraints on the spin-dependent WIMP (weakly interacting massive particle)-nucleon elastic cross sections from LUX data acquired in 2013. LUX is a dual-phase xenon time projection chamber operating at the Sanford Underground Research Facility (Lead, South Dakota), which is designed to observe the recoil signature of galactic WIMPs scattering from xenon nuclei. A profile likelihood ratio analysis of 1.4×10^{4}  kg day of fiducial exposure allows 90% C.L. upper limits to be set on the WIMP-neutron (WIMP-proton) cross section of σ_{n}=9.4×10^{-41}  cm^{2} (σ_{p}=2.9×10^{-39}  cm^{2}) at 33  GeV/c^{2}. The spin-dependent WIMP-neutron limit is the most sensitive constraint to date.

Improved Limits on Scattering of Weakly Interacting Massive Particles from Reanalysis of 2013 LUX Data

We present constraints on weakly interacting massive particles (WIMP)-nucleus scattering from the 2013 data of the Large Underground Xenon dark matter experiment, including 1.4×10^{4}  kg day of search exposure. This new analysis incorporates several advances: single-photon calibration at the scintillation wavelength, improved event-reconstruction algorithms, a revised background model including events originating on the detector walls in an enlarged fiducial volume, and new calibrations from decays of an injected tritium β source and from kinematically constrained nuclear recoils down to 1.1 keV. Sensitivity, especially to low-mass WIMPs, is enhanced compared to our previous results which modeled the signal only above a 3 keV minimum energy. Under standard dark matter halo assumptions and in the mass range above 4  GeV c^{-2}, these new results give the most stringent direct limits on the spin-independent WIMP-nucleon cross section. The 90% C.L. upper limit has a minimum of 0.6 zb at 33  GeV c^{-2} WIMP mass.